<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Newcelx Ltd. — News on 6ix</title>
<link>https://6ix.com/company/newcelx-ltd</link>
<description>Latest news and press releases for Newcelx Ltd. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 20 Apr 2026 11:37:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/newcelx-ltd" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d76f6d51cc36e47533d76a.webp</url>
<title>Newcelx Ltd.</title>
<link>https://6ix.com/company/newcelx-ltd</link>
</image>
<item>
<title>NewcelX Updates Corporate Presentation to Highlight Type 1 Diabetes Flagship Program Following Strategic Collaboration with Eledon Pharmaceuticals Ahead of Swiss Biotech Conference</title>
<link>https://6ix.com/company/newcelx-ltd/news/newcelx-updates-corporate-presentation-to-highlight-type-1-diabetes-flagship-program-following-strategic-collaboration-with-eledon-pharmaceuticals-ahead-of-swiss-biotech-conference</link>
<guid isPermaLink="true">https://6ix.com/company/newcelx-ltd/news/newcelx-updates-corporate-presentation-to-highlight-type-1-diabetes-flagship-program-following-strategic-collaboration-with-eledon-pharmaceuticals-ahead-of-swiss-biotech-conference</guid>
<pubDate>Mon, 20 Apr 2026 11:37:00 GMT</pubDate>
<description>ZURICH, Switzerland, April 20, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (Nasdaq: NCEL),– NewcelX Ltd. (Nasdaq: NCEL), a clinical-stage regenerative medicine company developing stem-cell-derived therapies, today announced the release of an updated corporate presentation that includes the company’s strategic collaboration with Eledon Pharmaceuticals (Nasdaq: ELDN) and highlights the advancement of its flagship Type 1 Diabetes program, NCEL-101, as a central pillar of the company’s development strateg</description>
</item>
<item>
<title>NewcelX Announces Pricing of $1.35 Million Equity Financing at 30% Premium Pricing</title>
<link>https://6ix.com/company/newcelx-ltd/news/newcelx-announces-pricing-of-dollar135-million-equity-financing-at-30percent-premium-pricing</link>
<guid isPermaLink="true">https://6ix.com/company/newcelx-ltd/news/newcelx-announces-pricing-of-dollar135-million-equity-financing-at-30percent-premium-pricing</guid>
<pubDate>Wed, 01 Apr 2026 04:00:00 GMT</pubDate>
<description>Financing reflects strong investor confidence and supports advancement of lead Type 1 Diabetes program ZURICH, Switzerland, April 01, 2026 (GLOBE NEWSWIRE) --</description>
</item>
<item>
<title>NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 Diabetes</title>
<link>https://6ix.com/company/newcelx-ltd/news/newcelx-announces-strategic-collaboration-with-eledon-pharmaceuticals-to-advance-ncel-101-program-for-type-1-diabetes</link>
<guid isPermaLink="true">https://6ix.com/company/newcelx-ltd/news/newcelx-announces-strategic-collaboration-with-eledon-pharmaceuticals-to-advance-ncel-101-program-for-type-1-diabetes</guid>
<pubDate>Mon, 09 Mar 2026 04:00:00 GMT</pubDate>
<description>Collaboration Integrates Stem-Cell-Derived Islets with Targeted Immune ModulationZURICH, Switzerland, March 9, 2026 /PRNewswire/ -- NewcelX Ltd. ("NewcelX")</description>
</item>
<item>
<title>NewcelX Reports Peer-Reviewed Publication Supporting Mazindol IR/SR and Advances CVR Monetization Strategy</title>
<link>https://6ix.com/company/newcelx-ltd/news/newcelx-reports-peer-reviewed-publication-supporting-mazindol-irsr-and-advances-cvr-monetization-strategy</link>
<guid isPermaLink="true">https://6ix.com/company/newcelx-ltd/news/newcelx-reports-peer-reviewed-publication-supporting-mazindol-irsr-and-advances-cvr-monetization-strategy</guid>
<pubDate>Thu, 12 Feb 2026 12:00:00 GMT</pubDate>
<description>NewcelX Ltd. ("NewcelX" or the "Company") (Nasdaq: NCEL), a clinical-stage biopharmaceutical company advancing stem-cell-derived therapies for Type 1 Diabetes and advancing innovative therapies for central nervous system (CNS) today announced the publication of a comprehensive peer-reviewed scientific review entitled, "Mazindol Immediate-Release/Sustained-Release (IR/SR): A 50-Year Legacy of Multifaceted Mechanisms and Emerging Therapeutic Potential," in Clinical Drug Investigation, a Springer N</description>
</item>
<item>
<title>NewcelX Announces Updated Corporate Presentation Ahead of Key Spring 2026 Investor and Partnering Conferences</title>
<link>https://6ix.com/company/newcelx-ltd/news/newcelx-announces-updated-corporate-presentation-ahead-of-key-spring-2026-investor-and-partnering-conferences</link>
<guid isPermaLink="true">https://6ix.com/company/newcelx-ltd/news/newcelx-announces-updated-corporate-presentation-ahead-of-key-spring-2026-investor-and-partnering-conferences</guid>
<pubDate>Thu, 29 Jan 2026 05:00:00 GMT</pubDate>
<description>Reinforces strategic focus on Type 1 Diabetes cell therapy and highlights expansion of Scientific Advisory Board and leadership teamZURICH, Jan. 29, 2026</description>
</item>
<item>
<title>NewcelX Announce Positive Results from International Collaborative Study Exploring Advanced Biomaterial Approaches for Stem Cell-Derived Islet Delivery in Type 1 Diabetes Without Immune Suppression</title>
<link>https://6ix.com/company/newcelx-ltd/news/newcelx-announce-positive-results-from-international-collaborative-study-exploring-advanced-biomaterial-approaches-for-stem-cell-derived-islet-delivery-in-type-1-diabetes-without-immune-suppression</link>
<guid isPermaLink="true">https://6ix.com/company/newcelx-ltd/news/newcelx-announce-positive-results-from-international-collaborative-study-exploring-advanced-biomaterial-approaches-for-stem-cell-derived-islet-delivery-in-type-1-diabetes-without-immune-suppression</guid>
<pubDate>Mon, 12 Jan 2026 05:00:00 GMT</pubDate>
<description>ZURICH, Jan. 12, 2026 /PRNewswire/ -- NewcelX Ltd. (Nasdaq: NCEL) ("NewcelX" or the "Company"), a clinical-stage biotechnology company advancing regenerative</description>
</item>
<item>
<title>NewcelX Appoints Dr. Julien Boisdron, a Swiss Big Pharma Leader in Diabetes Innovation, to Its Scientific Advisory Board</title>
<link>https://6ix.com/company/newcelx-ltd/news/newcelx-appoints-dr-julien-boisdron-a-swiss-big-pharma-leader-in-diabetes-innovation-to-its-scientific-advisory-board</link>
<guid isPermaLink="true">https://6ix.com/company/newcelx-ltd/news/newcelx-appoints-dr-julien-boisdron-a-swiss-big-pharma-leader-in-diabetes-innovation-to-its-scientific-advisory-board</guid>
<pubDate>Mon, 05 Jan 2026 12:00:00 GMT</pubDate>
<description>NewcelX Ltd. (NASDAQ: NCEL) ("NewcelX"), a biotechnology company developing cell-based and small-molecule therapies for neurodegenerative and metabolic diseases, today announced the appointment of Dr. Julien Boisdron, MD, a seasoned diabetes expert with extensive experience in Swiss big pharma leadership to its Scientific Advisory Board ("SAB").</description>
</item>
<item>
<title>NewcelX Expands Intellectual Property Footprint with Publication of DOXA Patent Application in China</title>
<link>https://6ix.com/company/newcelx-ltd/news/newcelx-expands-intellectual-property-footprint-with-publication-of-doxa-patent-application-in-china</link>
<guid isPermaLink="true">https://6ix.com/company/newcelx-ltd/news/newcelx-expands-intellectual-property-footprint-with-publication-of-doxa-patent-application-in-china</guid>
<pubDate>Thu, 11 Dec 2025 05:00:00 GMT</pubDate>
<description>Publication in key market advances NewcelX's global IP strategy across Asia and supports the Company's expanding position in neurology and metabolic</description>
</item>
<item>
<title>NewcelX Strengthens Scientific Advisory Board with Appointment of Jeremy Shefner, MD, PhD, Chief Medical Officer at the Barrow Neurological Institute</title>
<link>https://6ix.com/company/newcelx-ltd/news/newcelx-strengthens-scientific-advisory-board-with-appointment-of-jeremy-shefner-md-phd-chief-medical-officer-at-the-barrow-neurological-institute</link>
<guid isPermaLink="true">https://6ix.com/company/newcelx-ltd/news/newcelx-strengthens-scientific-advisory-board-with-appointment-of-jeremy-shefner-md-phd-chief-medical-officer-at-the-barrow-neurological-institute</guid>
<pubDate>Mon, 17 Nov 2025 05:00:00 GMT</pubDate>
<description>ZURICH and NESS ZIONA, Israel, Nov. 17, 2025 /PRNewswire/ -- NewcelX Ltd. (Nasdaq: NCEL) ("NewcelX" or "the Company"), a clinical-stage biotechnology company</description>
</item>
<item>
<title>NewcelX Announces Scientific Leadership with the Head of Division of Medical Neurosciences at the Department of Neurology at Hadassah, Prof. Tamir Ben-Hur on Its Scientific Advisory Board</title>
<link>https://6ix.com/company/newcelx-ltd/news/newcelx-announces-scientific-leadership-with-the-head-of-division-of-medical-neurosciences-at-the-department-of-neurology-at-hadassah-prof-tamir-ben-hur-on-its-scientific-advisory-board</link>
<guid isPermaLink="true">https://6ix.com/company/newcelx-ltd/news/newcelx-announces-scientific-leadership-with-the-head-of-division-of-medical-neurosciences-at-the-department-of-neurology-at-hadassah-prof-tamir-ben-hur-on-its-scientific-advisory-board</guid>
<pubDate>Thu, 06 Nov 2025 05:00:00 GMT</pubDate>
<description>ZURICH, Nov. 6, 2025 /PRNewswire/ -- NewcelX Ltd. (NASDAQ: NCEL) ("NewcelX" or the "Company"), a biotechnology company advancing transformative therapies for</description>
</item>
<item>
<title>NewcelX CEO Issues Letter to Shareholders</title>
<link>https://6ix.com/company/newcelx-ltd/news/newcelx-ceo-issues-letter-to-shareholders</link>
<guid isPermaLink="true">https://6ix.com/company/newcelx-ltd/news/newcelx-ceo-issues-letter-to-shareholders</guid>
<pubDate>Tue, 04 Nov 2025 05:00:00 GMT</pubDate>
<description>ZURICH, Nov. 4, 2025 /PRNewswire/ -- NewcelX Ltd. (Nasdaq: NCEL), a Swiss clinical-stage biopharmaceutical company developing cell-based and small-molecule</description>
</item>
<item>
<title>NewcelX Provides Business and Strategic Roadmap Update Following Closing of Merger with NLS Pharmaceutics Ltd.</title>
<link>https://6ix.com/company/newcelx-ltd/news/newcelx-provides-business-and-strategic-roadmap-update-following-closing-of-merger-with-nls-pharmaceutics-ltd</link>
<guid isPermaLink="true">https://6ix.com/company/newcelx-ltd/news/newcelx-provides-business-and-strategic-roadmap-update-following-closing-of-merger-with-nls-pharmaceutics-ltd</guid>
<pubDate>Mon, 03 Nov 2025 13:25:00 GMT</pubDate>
<description>NewcelX Ltd. (Nasdaq: NCEL) ("NewcelX" or the "Company"), a Swiss clinical-stage biopharmaceutical company developing cell-based and small-molecule therapies for neurodegenerative and metabolic diseases, integrating regenerative medicine and neuroscience expertise within a unified platform, today announced that it has posted an investor presentation on its website.</description>
</item>
<item>
<title>NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Completion of Merger</title>
<link>https://6ix.com/company/newcelx-ltd/news/nls-pharmaceutics-ltd-and-kadimastem-ltd-announce-completion-of-merger</link>
<guid isPermaLink="true">https://6ix.com/company/newcelx-ltd/news/nls-pharmaceutics-ltd-and-kadimastem-ltd-announce-completion-of-merger</guid>
<pubDate>Thu, 30 Oct 2025 20:15:00 GMT</pubDate>
<description>NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Completion of Merger</description>
</item>
</channel>
</rss>